Ownership and insider activity for CervoMed Inc. (CRVO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
Price
| Price | $2.44 |
| Market Cap | $23M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-11 | BOGER JOSHUA S | P-Purchase | 955,414 | $3.0M |
| 2026-06-11 | BOGER JOSHUA S | P-Purchase | 955,414 | $3.2M |
| 2026-06-11 | BOGER JOSHUA S | P-Purchase | 955,414 | $3.0M |
| 2026-06-08 | ZAVRL FRANK | A-Award | 8,150 | $24K |
| 2026-06-08 | Sabbagh Marwan | A-Award | 8,150 | $24K |
| 2026-06-08 | Quigley David | A-Award | 8,150 | $24K |
| 2026-06-08 | Poulton Jeffrey V. | A-Award | 8,150 | $24K |
| 2026-06-08 | Hollingsworth Jane H | A-Award | 8,150 | $24K |
| 2026-06-08 | Gregoire Sylvie | A-Award | 8,150 | $24K |
| 2026-06-08 | BOGER JOSHUA S | A-Award | 8,150 | $24K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $8.9M | $8.0M | $14.2M | $18.5M | $37.3M | $4.1M | $7.8M | $9.0M | $8.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $29.9M | $12.6M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $915404 | $2.3M | $426993 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.6M | $9.7M | $8.9M | $14.6M | $18.8M | $37.8M | $4.2M | $10.0M | $43.1M | $22.6M |
| Property, Plant & Equipment | $79755 | $460652 | $350281 | $499409 | $298360 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | $6.9M | $6.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $8.6M | $8.6M | $8.6M | $8.6M | $8.6M | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $17.5M | $26.1M | $18.2M | $24.3M | $27.7M | $37.8M | $4.2M | $10.0M | $43.1M | $23.4M |
| Accounts Payable | $1.7M | $511956 | $198818 | $1.3M | $545844 | $947495 | $97302 | $662471 | $1.5M | $1.5M |
| Short-term Debt | $1.9M | $550000 | 0 | 0 | 0 | 0 | $12.4M | 0 | 0 | 0 |
| Total Current Liabilities | $4.4M | $2.7M | $804044 | $1.7M | $2.4M | $2.9M | $13.2M | $2.6M | $3.9M | $4.7M |
| Long-term Debt | $550000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $8.3M | $4.9M | $2.6M | $4.1M | $2.9M | $2.9M | $13.2M | $2.6M | $3.9M | $5.2M |
| Retained Earnings | -$60.2M | -$61.6M | -$79.9M | -$91.7M | -$105.9M | -$130.0M | -$52.3M | -$54.4M | -$70.7M | -$97.7M |
| Total Equity | $9.2M | $21.2M | $15.6M | $20.1M | $24.8M | $34.9M | -$9.0M | $7.4M | $39.2M | $18.2M |
| Total Debt | $2.4M | $550000 | 0 | $247043 | $149162 | 0 | $12.4M | 0 | 0 | 0 |
| Net Debt | $877148 | -$8.3M | -$8.0M | -$13.9M | -$18.4M | -$37.3M | $8.3M | -$7.8M | -$38.9M | -$20.9M |
| Working Capital | -$2.8M | $7.0M | $8.1M | $12.9M | $16.3M | $34.9M | -$9.0M | $7.4M | $39.2M | $17.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.57 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -0.64 |
Profitability
| Return on Equity | -156.02% |
| Return on Invested Capital | -135.73% |
| Return on Assets | -116.76% |
| Gross Margin | 100.00% |
| Operating Margin | -9661.43% |
| Net Margin | -9408.76% |
Related companies: ACET · ADAG · FBIO · GANX · LITS · NRXP · NTRB
Explore sector: Healthcare · Biotechnology
More sections of CRVO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks